the many alterations in microsatellite loci seen during Raymond L. White somatic development of tumors with defects in their Eccles Institute of Human Genetics DNA repair systems (Ionov et al., 1993) . As the microsatHoward Hughes Medical Institute ellite alterations usually do not directly affect gene activUniversity of Utah ity, it seems unlikely that these alterations are under Salt Lake City, Utah 84112 positive selection. Yet mutant alleles of microsatellites are abundantly represented among this subset of tumors. The search for the tumor suppressor gene on 18q Identification of the cell regulatory genes that drive carexemplifies this challenge. The initial candidate gene cinogenesis is one of the major goals in cancer research, identified in the 18q region, DCC, seemed at first to resulting in new anticancer drug targets and new therameet the appropriate criteria for a tumor suppressor peutic and diagnostic approaches. Colon cancer is one gene (Fearon et al., 1990) . It was a large gene and restricof the best-characterized tumor systems from the pertion fragment alterations were seen in approximately spective of understanding the genetic events that under-10% of tumors. However, the sequences responsible lie the development of malignancy. One reason for the for these alterations were found to be present in an detailed knowledge available in this system is the identiintron rather than an exon, and resulted from variation fication of an intermediate in the progression pathway, in a microsatellite sequence. At that time, however, it the adenomatous polyp, accessible for both histological had not been shown that microsatellite regions show a and molecular analysis. Characterization of the polyp high frequency of background variation in a subset of intermediate has allowed discrimination between initiatcolon carcinomas, and it appeared that DCC might be ing events and progression events. Mutations in the the tumor suppressor gene driving the frequent LOH. APC gene, for example, are found in the earliest polyps, However, very few of the mutations expected to be seen initiating the development of both inherited and sporadic in the coding sequences of the retained allele were recolon adenomas (Groden et al., 1991; Joslyn et al., 1991;  vealed in a search of a large sample set of colon tumors Kinzler et al., 1991; Nishisho et al., 1991) . The finding (Cho et al., 1994) . Other tests were needed to resolve that the APC protein is capable of modulating levels of the issue. ␤-catenin protein, a downstream effector of the Wnt
The report of Takaku et al. (1998) in this issue of Cell signaling pathway (Rubinfeld et al., 1993; Su et al., 1993) , now adds substantial support for a major role for another suggested that this pathway may be the regulatory tarimportant signaling system in colon carcinogenesis, the get of the APC protein. Recent findings of somatic muta-TGF␤ pathway, in regulating the progression of the colon tions in ␤-catenin that relieve modulation by APC protein adenoma to carcinoma. Takaku et al. have examined confirm the etiologic role of this pathway in colon carcithe role of the SMAD4 gene, which maps to the same nogenesis (Morin et al., 1996 (Morin et al., , 1997 .
region of 18q as DCC, in mediating the progression An important role for another tumor suppressor gene of intestinal adenomas to carcinoma. Normally, TGF␤ involved in colon tumor progression is suggested by the provides a growth-inhibiting differentiation signal in epiobservation of frequent loss of heterozygosity of DNA thelial cells such as breast and colon. Two-receptors, marker loci on chromosome 18q in colon tumors (Fearon TGF␤RI and TGF␤RII, govern the interaction between et al., 1990) . Because mutations in tumor suppressor the cell and the TGF␤ ligand. Primary binding of the genes are recessive at the cell level, heterozygous cells ligand occurs with the RII receptor, promoting formation require loss or inactivation of the normal allele in order of a heterodimer with TGF␤RI and activation of signaling. to reveal their tumorigenic phenotype. Often the normal This leads to a complex set of downstream interactions. allele is lost through a large deletion, sometimes even
The best understood of these is mediated by the SMAD of the entire chromosome or chromosome arm. Chromofamily of proteins. SMADs 1, 2, and 3 show tissue specisomal locations of tumor suppressor genes are, thereficity and have a transactivation domain. SMAD4, on fore, frequently determined by loss of heterozygosity the other hand, is ubiquitously expressed but without (LOH) at DNA marker loci (Cavenee et al., 1983; Li et al., a transactivation domain. However, SMAD4 does form 1997), setting the stage for a positional cloning effort.
oligomers with each of SMADs 1, 2, and 3 that promote A prediction is that the residual tumor suppressor gene, their translocation to the nucleus (Zhang et al., 1997) . whose functional loss is reflected by the LOH, should
This pathway was initially implicated in a subset of carry a mutation. This is important, as there are often colon tumors by observation of mutations in the gene several or more candidates in the region defined by encoding TGF␤ receptor type II associated with the mumapping.
tator phenotype of HNPCC syndrome (Markowitz et al., Because many genes show a low frequency of muta-1995). These mutations result from insertions or deletions in tumors, however, a finding of only a low fretions of one or a few bases and ablate the cell response quency of mutation in a candidate gene must be reto TGF␤ signaling. However, these mutations represent garded with caution. An additional confounding problem only a small minority of colon tumors. is that tumors evolve clonally. A change that occurs Important support for a more general role for this early during tumorigenesis may be carried along during pathway in carcinogenesis came with the finding that the growth and evolution of the tumor without having mutations in two downstream effector components of the TGF␤ signaling pathway, SMAD4 and SMAD2, could served an etiologic role. A good example is provided by be found in colon carcinomas (Eppert et al., 1996; Thia- evidence, both mutational and functional, are needed to confirm identification of a somatically defined tumor galingam et al., 1996) . Their role was suggested by the finding of a high frequency of mutation in SMAD4 in suppressor. The finding of a low frequency of mutation in a candidate should not be taken as adequate proof. pancreatic tumors (Hahn et al., 1996) and the location of SMAD4 on human chromosome 18q, in the region Furthermore, the finding that each of SMAD4 and SMAD2 can show mutations in tumors, and that inactithat shows frequent LOH in colon and other carcinomas (Fearon et al., 1990) . The mouse knockout observations vating mutations of either would be expected to abrogate the TGF␤ signaling pathway, suggests that each reported by Takaku provide additional strong evidence that SMAD4 is a suppressor of colon tumor progression. may be capable of inactivating the tumor suppressor pathway. Which gene actually drives progression in a The Takaku experiment depends on the fact that in mice, the APC gene locus and the SMAD4 locus are specific tumor may only depend on which is the first to be mutated. both located on the same chromosome. Furthermore, in mice heterozygous for a mutant APC allele (polyposis Selected Reading mice), virtually all intestinal adenomas will have lost the entire chromosome that carries the normal APC allele.
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